August 11, 2009
A large effectiveness study comparing Schering-Plough's pegylated-interferon Pegintron and ribavirin with Roche's Pegasys and ribavirin shows both hepatitis C treatments worked equally well.
The study by Dr. Mark Sulkowski of Johns Hopkins University involved 3,000 patients with hepatitis C. Its findings are meant to help guide doctors' decisions about which treatments work best.
"There has been a lot of debate about these two regimens," said Dr. Andrew Muir of Duke University, a co-author of the Schering-Plough-funded study. "It's great to have a study of this size that really answers this question."
07.22.2009; Julie Steenhuysen
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|